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Abstract
The objective of the present study was to assess the effects of the immunosuppressant rapamycin (Rapamune®, Sirolimus) on 
both resistance vessel responsiveness and atherosclerosis in apolipoprotein E-deficient 8-week-old male mice fed a normal 
rodent diet. Norepinephrine (NE)-induced vasoconstriction, acetylcholine (ACh)- and sodium nitroprusside (SNP)-induced 
vasorelaxation of isolated mesenteric bed, and atherosclerotic lesions were evaluated. After 12 weeks of orally administered 
rapamycin (5 mg·kg-1·day-1, N = 9) and compared with untreated (control, N = 9) animals, rapamycin treatment did not modify 
either NE-induced vasoconstriction (maximal response: 114 ± 4 vs 124 ± 10 mmHg, respectively) or ACh- (maximal response: 
51 ± 8 vs 53 ± 5%, respectively) and SNP-induced vasorelaxation (maximal response: 73 ± 6 vs 74 ± 6%, respectively) of the 
isolated vascular mesenteric bed. Despite increased total cholesterol in treated mice (982 ± 59 vs 722 ± 49 mg/dL, P < 0.01), 
lipid deposition on the aorta wall vessel was significantly less in rapamycin-treated animals (37 ± 12 vs 68 ± 8 µm2 x 103). 
These results indicate that orally administered rapamycin is effective in attenuating the progression of atherosclerotic plaque 
without affecting the responsiveness of resistance vessels, supporting the idea that this immunosuppressant agent might be of 
potential benefit against atherosclerosis in patients undergoing therapy.
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Rapamycin (Rapamune®, Sirolimus) is an antifungal 
agent with antiproliferative and immunosuppressant 
properties used to prevent rejection of transplanted 
organs (1). The mechanism of action of rapamycin is a 
blockade of the response of T and B cells to cytokines, 
thereby preventing cell cycle progression in G1 and cell 
proliferation (2). The primary vascular effects of this drug 
include the inhibition of smooth muscle and endothelial 
cell proliferation (3).
Abnormal vascular smooth muscle cell proliferation 
and migration contribute to the development of restenosis 
after percutaneous transluminal coronary angioplasty 
(4). Rapamycin has also been shown to be effective in 
decreasing coronary artery restenosis in humans when 
eluted from implanted stents and, consequently, this 
treatment is commonly used in percutaneous coronary 
interventions (5,6). However, some studies, which fo-
cused on the understanding of the effects of this drug on 
vascular function, have shown that, in contrast to bare 
metal stents, rapamycin-eluting stents impair endothe-
lial function, as indicated by an acetylcholine-induced 
coronary vasoconstrictive response in the proximal and 
distal stent segments (7,8). 
Oral administration of rapamycin has been proposed 
as an alternative to drug-eluting stents, especially when 
multiple stenting is recommended (9), thus raising the 
necessity to investigate the potential effects of this agent 
on the vessels. Focusing on this issue, Milliard et al. 
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(10) showed that systemic treatment with rapamycin (2 
mg/kg) for 2 weeks attenuated the vasoconstriction and 
potentiated the endothelium-dependent vasorelaxation 
of aortic rings in Sprague-Dawley rats. In contrast, Neto 
et al. (11) showed that orally administered rapamycin at 
the same dose and for the same treatment duration did 
not affect the vascular tone of Wistar rats. Alternatively, 
studies on mice have been limited to the evaluation of the 
effects of rapamycin on the progression of atherosclerotic 
plaque in apolipoprotein E (apoE) knockout mice fed a 
high-cholesterol diet (12,13). However, we should con-
sider the physiological importance of studying the effect 
of this drug on the responsiveness of resistance vessels 
and on atherosclerosis in this murine model of spontane-
ous atherosclerosis without the perturbation caused by a 
supplemented high-fat diet. Therefore, the present study 
was designed to assess the effects of orally administered 
rapamycin on the vasoconstriction and vasodilation of the 
vascular mesenteric bed and on the atherosclerotic plaque 
of apoE knockout mice fed a normal rodent diet.
Material and Methods
Animals and treatment 
Experiments were conducted on young (eight weeks of 
age; averaging 23 g) male apoE knockout mice obtained 
from the animal facilities of the Health Sciences Center, 
Federal University of Espírito Santo. The animals were fed 
a normal chow rodent diet and water ad libitum. All animal 
procedures were approved in advance by the institutional 
Ethics Committee for Use of Animals (CEUA-EMESCAM, 
Protocol #022/2007) and were conducted in accordance 
with the international guidelines for care and use of labora-
tory animals.
Rapamycin (Rapamune®, Wyeth-Ayerst, USA) was 
admixed with the diet of the treated group to deliver an oral 
dose of 5 mg/kg per day for 12 weeks. 
Preparation of the mesenteric arteriolar bed 
The superior mesenteric artery was cannulated using 
a catheter (0.040 mm OD x 0.025 ID; Micro-Renathane®; 
Braintree Science) under thiopental (40 mg/kg, ip) anes-
thesia. The mesenteric arteriolar bed was then placed in 
a vessel containing water at 37°C and perfused at a con-
stant rate (2 mL/min) with oxygenated (95% O2-5% CO2 
mixture) physiological salt solution using a roller pump 
(Harvard Apparatus, USA). The composition of the solu-
tion was as follows: 130 mM NaCl, 4.7 mM KCl, 1.6 mM 
CaCl2.2H2O, 1.8 mM KH2PO4, 1.17 mM MgSO4.7H2O, 
14.9 mM NaHCO3, 0.026 mM EDTA, and 11.1 mM glucose. 
Perfusion pressure was monitored via a T-tube inserted 
between the pump and the inflow cannula and connected 
to a pressure transducer (Cobe Laboratories, USA) and 
a data acquisition system (BioPac Systems, USA). First, 
we studied the dose-dependent contractions to 0.1 µM to 
0.2 M norepinephrine (NE; Sigma Chemical Co., USA). 
To study endothelial function, vasodilator responses to 1 
nM to 10 mM acetylcholine (ACh; Sigma) and 1 nM to 10 
mM sodium nitroprusside (SNP; Sigma) were calculated 
as percent reduction in the precontractions induced by 
5 µM NE (a concentration that induces 60 to 80% of the 
maximal effect).
Measurement of plasma cholesterol levels 
A blood sample was taken from the carotid artery and 
total plasma cholesterol was measured using a commercial 
colorimetric kit (Bioclin, Brazil).
Histological vessel processing and morphometry
Immediately after the isolation and removal of the vas-
cular mesenteric bed, the animals were perfused via the 
left ventricle with 0.1 M phosphate-buffered saline, pH 7.4, 
followed by a fixative solution containing 4% paraformal-
dehyde. After overnight incubation in the fixative solution, 
the heart and the ascending aorta were embedded in 24% 
(w/v) gelatin solution, and 10-µm serial sections were cut 
from the level of the aortic valve leaflets up to the curve of 
the aorta arch with a -20°C cryostat (Jung CM 1800, Leica, 
Germany). Aorta cross-sections were mounted on gelatin-
coated slides and stained with either oil-red-O (Sigma) for 
the detection of neutral lipids or with hematoxylin-eosin 
(Sigma) for morphological analysis performed by an inde-
pendent investigator.
Images were captured with a color video camera (VK-
C150, Hitachi, Japan) connected to a microscope (Olympus 
AX70, USA) and analyzed with a specific image program 
(2100 Leica EWS, Germany) by an examiner blinded to the 
treatment group. The lipid deposition area was quantified 
by selecting and averaging the five most highly stained 
cross-sections of the aorta of each animal.
Statistical analysis
Data are reported as means ± SEM. Statistical analysis 
was performed by two-way ANOVA followed by the Fisher 
test for multiple comparisons. Comparisons of mean values 
between two groups were performed by the unpaired Stu-
dent t-test whenever needed. A two-tailed P ≤ 0.05 value 
was accepted as statistically significant.
Results
ApoE-deficient mice treated with orally administered 
rapamycin gained similar amounts of body weight and were 
as active as control mice. 
The data in Figure 1 provide the dose-effect curve for 
NE, ACh and SNP in long-term rapamycin-treated and 
control apoE-deficient mice. The basal perfusion pressure 
of the isolated mesenteric bed was similar in both groups. 
The vascular constriction response to NE was also similar 
in treated and control animals, as indicated by the maximal 
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response (114 ± 4 vs 124 ± 10 mmHg, respectively) and 
the logED50 (-2.80 ± 0.04 vs -2.90 ± 0.09 M, respectively). 
The endothelium-dependent relaxation in response to 
ACh was similar in treated and control mice in terms of 
maximal response (51 ± 8 vs 53 ± 5%, respectively) and 
logED50 (-5.40 ± 0.40 vs -5.80 ± 0.31 M, respectively). The 
endothelium-independent vascular smooth muscle relax-
ation to SNP was also unchanged by rapamycin treatment 
compared to control mice: maximal response (73 ± 6 vs 
74 ± 6%, respectively) and logED50 (-5.78 ± 0.51 vs -5.31 
± 0.31 M, respectively).
Plasma cholesterol levels were significantly higher in 
rapamycin-treated than in control animals (982 ± 59 vs 722 
± 49 mg/dL, P < 0.01).
Figure 2 shows typical microphotographs of aortic root 
sections. Rapamycin-treated mice displayed a marked 
reduction in the area of oil-red-O-stained atherosclerotic 
plaque compared with control mice. The average values 
of lipid deposition in the vessel sections were significantly 
less in treated than in control animals (37 ± 12 vs 68 ± 8 
µm2 x 103; bar graph in Figure 2). 
Discussion
In the present study, we show that long-term orally 
administered rapamycin attenuates the development of 
vascular atherosclerotic plaque, but does not affect either 
the vasoconstriction induced by NE or the endothelium-
dependent vasorelaxation induced by ACh in apoE-deficient 
mice fed a normal diet. 
The development of drug-eluting stents, and in par-
ticular rapamycin-coated stents, was a milestone in the 
treatment of obstructive coronary atherosclerosis disease. 
These new devices are associated with a dramatic and 
sustained reduction of the restenosis process, as can be 
observed from several clinical trials (6,14,15). In another 
field of application, oral administration of rapamycin has 
been proposed as an alternative to drug-eluting stents for 
preventing in-stent restenosis after percutaneous coronary 
intervention (9,16,17). However, it is important to establish 
other benefits of rapamycin, including the regression of ath-
erosclerosis that affects mainly large conductance vessels 
and the control of the circulation that is mainly exerted by 
resistance vessels, as well as to address concerns regard-
ing toxicity and late adverse side effects (14).
Regarding the effects of systemic treatment with ra-
pamycin on arterial vessel tone and endothelial function, 
studies have been restricted to the rat and have shown 
conflicting results (10,11). One of these two studies showed 
that rapamycin significantly attenuated the vasoconstriction 
and potentiated the endothelium-dependent vasorelaxation 
of aortic rings (10) and the other showed that orally ad-
ministered rapamycin at the same dose and for the same 
treatment duration did not affect the vascular tone (11). 
Because this experimental animal does not develop athero-
Figure 1. Concentration-dependent contraction of isolated 
mesenteric arteries of apolipoprotein E-deficient mice in re-
sponse to norepinephrine (NE) and endothelium-dependent 
relaxation in response to acetylcholine (ACh) or endothelium-
independent relaxation to sodium nitroprusside (SNP). The 
mice received 5 mg/kg rapamycin daily for 12 weeks (treated) 
and were compared with untreated (control) animals. Each 
point indicates means ± SEM.
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sclerosis, the effect of systemic administration of rapamycin 
on atherosclerosis could not be considered. 
Following the advancement of molecular biology and 
the development of gene knockout technology, the apoE-
deficient mouse has become a valuable tool in elucidating 
mechanisms and assessing therapeutic strategies against 
atherosclerosis and other cardiovascular diseases. In the 
present study, we demonstrate that orally administered 
rapamycin (5 mg/kg, for 12 weeks) does not modify the 
vascular constriction in response to NE or the vascular re-
laxation in response to ACh (endothelium-dependent action) 
or SNP (endothelium-independent action) of isolated arterial 
mesenteric beds in apoE-deficient mice fed a normal rodent 
diet. Although the murine model of atherosclerosis is not 
fully comparable to the human situation, the present result 
is important because it shows that long-term administration 
of high doses of rapamycin maintains the normal function 
of resistance vessels, which is an important consideration 
favoring the therapeutic use of this immunosuppressant 
agent in transplant patients. Further experiments are 
necessary to determine if rapamycin also preserves the 
normal responsiveness of conductance vessels (aorta) in 
the murine model of spontaneous atherosclerosis. 
In our study, apoE-deficient mice showed high total 
serum cholesterol levels, in agreement with results from 
the investigators who introduced this murine model (18,19) 
and with previous studies from our group (20,21). We 
observed that orally administered rapamycin increased 
total cholesterol levels in apoE-deficient mice fed a normal 
rodent diet compared with untreated animals. Interest-
ingly, when hypercholesterolemia in apoE-deficient mice 
is severely aggravated by a high-fat supplemented diet, 
the hypercholesterolemic effect of rapamycin has been 
observed by some (22) but not by others even with the use 
of a high-dose, long-term rapamycin treatment (13,23,24). 
Importantly, our result obtained in this murine model of 
spontaneous atherosclerosis agrees with the general clinical 
concept that the increase in cholesterol is a side effect of 
rapamycin treatment (25).
There is a consensus that rapamycin significantly re-
duces the aortic atherosclerotic plaque in apoE-deficient 
mice fed a fat-rich diet (12,13,22,23,26). In the present 
study, we also observed similar anti-atherosclerotic effects 
of rapamycin administered to the apoE-deficient mice fed a 
normal rodent diet. On the basis of other studies, there are 
several possible mechanisms by which rapamycin, in addi-
tion to being a potent immunosuppressant and antiprolifera-
tive agent, could decrease vascular atherosclerotic lesions. 
One of the first studies showed that orally administered 
rapamycin significantly inhibited aortic smooth muscle cell 
migration (4). Oral rapamycin also effectively slows the 
progression of atherosclerosis by attenuating monocyte 
chemotaxis (13). Ma et al. (27) showed that inhibition of 
lipid uptake together with increasing cholesterol efflux and 
the inhibition of inflammatory cytokines are all important 
aspects of the anti-atherosclerotic effects of rapamycin on 
smooth muscle cells. In addition, overexpression of eNOS 
may also contribute to the changes observed in the aorta 
of apoE-deficient mice induced by rapamycin (24).
The data presented here indicate that orally adminis-
Figure 2. Effect of oral rapamycin (treated) for 12 weeks on atherosclerotic plaque formation in apolipoprotein E-deficient mice com-
pared to untreated (control) mice. Typical photomicrographs, at low (40X) and high (100 to 400X) magnification, are from aortic root 
sections stained with oil-red-O to visualize lipid-rich lesions and counterstained with hematoxylin-eosin. Histogram shows the average 
lipid deposition area in aortic root sections. Data are reported as means ± SEM. *P < 0.05 vs control group (Student t-test).
Vascular effects of rapamycin in apoE-deficient mice 1195
www.bjournal.com.br Braz J Med Biol Res 42(12) 2009
tered rapamycin is effective in attenuating the progression of 
atherosclerotic plaque without affecting the responsiveness 
of resistance vessels, suggesting that this immunosuppres-
sant agent might be of benefit regarding atherosclerosis 
in patients undergoing therapy, independent of changes 
in circulating lipids.
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